TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an announcement.
OncoSil Medical Limited announced significant achievements in FY25, including regulatory progress and commercial expansion. The approval from Germany’s G-BA for a fully funded clinical trial is expected to enhance access to the OncoSil™ device in the German public hospital system, potentially influencing reimbursement negotiations across Europe. Additionally, the company achieved MDR certification, streamlining treatment initiation in the EU and UK, and recorded its first commercial sale in Germany. Clinical trials like PANCOSIL and TRIPP-FFX are nearing completion, with promising results supporting the efficacy of the OncoSil™ device.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a medical device company specializing in localized treatments for patients with unresectable locally advanced pancreatic cancer. The company focuses on expanding access to targeted radiation options for pancreatic cancer, aiming to improve survival rates in this challenging oncology area.
Average Trading Volume: 23,108
Technical Sentiment Signal: Sell
Current Market Cap: A$23.44M
For detailed information about OSL stock, go to TipRanks’ Stock Analysis page.